Life Sciences Archive » May, 2021

Life Sciences - May, 2021

327 articles

• Law360 Names 2021's Top Attorneys Under 40
• 10X Infringes Bio-Rad Patents, Federal Circuit Affirms
• Key Opioid Trials To Watch As Cases Heat Up Nationwide
• Kodak Suit Over Exec Stock Options, $765M Loan Sent To NY
• Fed. Circ. Reverses PTAB, Axes Baxter Telepharmacy Patent
• Elizabeth Holmes Wants 45-Page Questionnaire For Jurors
• Biden Science Adviser Approved By Senate
• GOP Introduces Bill That Would Ban Federal Vaccine Passport
• Eli Lilly Gets More Time To Respond To HHS Letter
• J&J Unit Must Face Warning Claims Over Neutrogena Wipes
• Venture Firm Can't Escape OvaScience IVF Suit, Judge Says
• Miss. Secretary Of State Won't Fight Ruling Nixing Medical Pot
• FDA Opts To Keep Unapproved Drug Program Axed By Trump
• Goodwin Steers Biotech Holding Firm's Upsized $330M IPO
• DEA Opens The Door To Pot Research. Is Legalization Next?
• 5 Tips To Help Your 2021 Summer Associates Succeed
• Illumina, Grail Say FTC Just Wants To Run Out Merger Clock
• JPML Weighs New Opioid MDL As McKinsey Suits Surge
• 3rd Circ. Says NJ Cap Doesn't Block Mesh Case Fees In Texas
• IP Forecast: Cell Giants To Defend Wireless Tech In EDTX
• Fla. High Court Upholds State's Medical Marijuana Framework
• Judge Questions Bid To Move Acthar Cases To Delaware
• Bayer May End Glyphosate Retail US Sales
• Tricida Directors Hit With Securities Suit Over Drug Approval
• Panel Hears 3 Venue Options For Crop Inputs MDL
• 5 Current Ad And Marketing Legal Risks To Watch Out For
• EU, AstraZeneca Spar Over Vaccine Delivery Deadlines
• It's Time For States To Enact Effective Marijuana DUI Laws
• Ex-Gilead Workers Hit Back With Sanctions Bid In FCA Fight
• Latham-Led Health Apparel Co. Leads 3 IPOs Totaling $964M
• Firms Should Use Surveys To Make Smart Legal Tech Choices
• Purdue Statement Gives Creditors Enough Info, Judge Says
• Suit Presses EPA To Enforce Air Pollution Standards
• Fla. Men Latest Charged For Bogus COVID Health Care Bills
• DOJ Nominee On Track As GOP Blasts 'Defense Judges'
• Startup Says Digital Health Co. Lied About Acquisition
• Mallinckrodt Ch. 11 Trustee Hearing Set For Confirmation
• Dems Start Quest For Centerpiece Of Biden's Health Agenda
• Chubb Unit Gets Dismissal Of Health System's $5M Virus Suit
• University Nurse's Negligence Wasn't 'State-Created Danger'
• McKool Smith Snags NY-Based IP Pair From King & Spalding
• Insurance Ruling Clarifies Excess Coverage For Opioid Suits
• Messner Reeves Adds Ex-Ropers Majeski Litigation Squad
• Okla. AG To Resign Amid Reports Of Extramarital Affair
• Judge Won't OK $2B Deal For Future Roundup Claims
• 3rd Circ. Backs Legal Funder In Contract Breach Appeal
• DOJ Wants Time During SmileDirect's Calif. Dental Board Args
• Actavis Inks $1.1M Deal In ADHD Medication Antitrust Suit
• Judge Revisits Grocer's Defense Dispute Over Opioid Injury
• IP Waiver Talks Hinge On Use Of Big Pharma's Trade Secrets
• Feds Fight Bid For High Court Review Of FCA Standard
• 8th Circ. Won't Revive Mentor Breast Implant Suit
• AMAG Escapes Suit Over Preterm Birth Drug's Effectiveness
• There Is No 'Junk Science' Epidemic In Consumer Litigation
• Don't Forget Due Diligence In Race For Lateral Associate Hires
• UK Regulator Will Scrutinize AstraZeneca-Alexion Deal
• Burns Scalo GC On The Hunger For Life Sciences Real Estate
• New Circuit Split Complicates Domestic Securities Test
• Former Trump HHS Counsel Rejoins Greenberg Traurig
• Coronavirus Regulations: A State-By-State Week In Review
• CBD Co. Seeks To Dodge Sanctions Bids In IP Row
• Senate Approves Manatt Phelps Vet For Top HHS Post
• Calif. Jury Hears Of Heartbreak In Case Of Destroyed Embryos
• Needles Litter Oakland, City Official Says In Opioid Trial
• Watchdog Backs DOD's Use Of Contentious $1B COVID Fund
• Cannabis Entrepreneurs' Family Fighting Spills Into Court
• DEA Can't Ban Psilocybin Therapy, States Tell 9th Circ.
• Purdue's New Ch. 11 Plan Docs Detail Claims Trust Framework
• MiMedx Not A Victim, Can't Get $40M Restitution In Fraud Suit
• Hagens Berman Loses Privilege In Thalidomide Sanction Fight
• Eli Lilly Says HHS Trying To Foil Case Over Drug Discounts
• Jury Can Hear Some Evidence Of Elizabeth Holmes' Wealth
• Gilead Gets PTAB To Wipe Out University's Antiviral IP Claims
• Drug Co. Says Emory Prof Backing False Probiotic Claims
• US, Claims Rep Challenge Mallinckrodt Ch. 11 Disclosures
• Ariosa, Illumina Resolve DNA Patent Dispute At High Court
• Addressing Environmental Justice As Part Of ESG Initiatives
• Trial Icon Hanly Remembered As Litigator's Litigator
• NJ Justices Won't Reconsider Ducking Fray Over Mesh Fees
• Justices Won't Hear Cancer Research Patent Fight
• 4th Circ. Halts Block On SC Horseshoe Crab Harvests
• Endo Investors Win Operatic Class Cert. In Generic Price Suit
• Claims Court Wants VA Medical Supply Deal Transfer Stopped
• Drugmakers Throw Purdue Under Bus In Opioid Trial Gamble
• Investor Brings Class Suit Over Surprise Diabetes Drug Delay
• Pharma Orgs Lay Out Vaccine Access Plan Without IP Waiver
• Shkreli, Vyera Rip FTC Sanction Bid Over Alleged Phone Wipe
• G-20 Health Accord Shows Split On Waiving COVID IP
• Pot Co. Harvest Wants Out Of Fight Over Arkansas Facility
• Midcase Appeal In Opioid Bellwether Not Needed, Tribe Says
• ITC To Probe Apple Watches In Portable EKG Patent Row
• Once Sizzling IPO Market Starts To Show Cracks
• Drug Industry Group Slams Mallinckrodt Ch. 11 Disclosures
• HIV Drug IP Waiver Success Should Guide COVID Vax Rollout
• GOP Lawmakers Look To Bar Visas For IP Thieves, Spies
• Health Hires: Freshfields, DLA Piper, Cozen O'Connor
• Lessons In Civility From The Alex Oh Sanctions Controversy
• Indian Drugmaker Morepen Nabs $100M From Corinth Group
• UK Litigation Roundup: Here's What You Missed In London
• IP Forecast: Customer Service Secrets Row Heads To Jury
• Industry Tells 9th Circ. No Cancer Warning For Glyphosate
• FTC To Focus On In-House Challenge Of Illumina Deal
• Canadian Hemp Co. Can't Escape US Contract, 6th Circ. Told
• Cigna Defeats Class Cert. Bid In ERISA Suit Over Drug Prices
• Ex-Insys CEO Escapes FCA Suit Over Opioid Bribes, For Now
• Dove 'Stain Defense' Lets Them See You Sweat, Suit Says
• Ill. Justices Side With Columbia Care Unit In Pot Grow Fight
• US, Global Tax Revamp Could Fill Vaccine Need, Study Says
• A Practical Metric For Annual Patent Filing Targets: Part 1
• Navigating Development Bank COVID-19 Relief Probes
• EPA Sued For Delay In Evaluating PVC As Hazardous Waste
• FTC Tells Justices To Nix Sham Litigation Exception Case
• Trade Groups Urge Justices To Review $600M NY Opioid Tax
• Mallinckrodt's Ch. 11 Claim Deadline OK'd Over Opposition
• Biz Record Admissibility Rule Must Adapt To An ESI World
• Cooley Adds Ex-Nelson Mullins IP, Life Sciences Pro In Boston
• Purdue Says It May Have To Push Back Ch. 11 Schedule
• Paper Mill Co-Owned By Robert Kraft Sued Over Air Pollution
• 5th Circ. Revives Conspiracy Case Against Quest Diagnostics
• Judge Raises Litigation Risks, Doubts In $2B Roundup Deal
• House Again Passes Bill To Reform Orphan Drug Exclusivity
• Biz Groups Back PBMs In North Dakota Preemption Fight
• Tilray Says Fla. Grower's Suit Is 'Improper' And 'Absurd'
• Merck Settles With UFCW Unit In Retroactive OT Suit
• Akin Gump Beefs Up In DC With Addition Of Ex-FDA Official
• Hikma Urges Justices To Skip Case On Obviousness Evidence
• Sens. Pitch Bill To Regulate CBD Products In Food And Drink
• Lessons From COVID Securities Rulings On Dismissal Bids
• Overlooked Patent Cases: Preclusion's Effect On Settlement
• GOP Sens. Bash COVID IP Waiver As 'Giveaway' To China
• What Attorneys Should Know About State MDLs
• Hagens Berman Suffers Privilege Defeat In Thalidomide Row
• Biogen Asks Justices To Review Pfizer's MS Drug Win
• 11th Circ. Hints Pharma Co.'s Fight With Gov't Mooted
• FTC Wants Shkreli Sanctioned For Allegedly Wiping Phone
• Ex-Doc Gets 59 Years For Unnecessary Surgeries, $21M Fraud
• Takeda Unit Inks Deal To End IP Suit After Bayer's $173M Win
• Paul Weiss Attys To Guide Roe V. Wade Defense At High Court
• US Chamber Backs Walmart In 5th Circ. Opioid Challenge
• CDC Pushed Tasks To White Colleagues, Ex-Worker Says
• Dems Call For FTC Probe Into AbbVie's Humira Deals
• Health Plans Win Class Cert. In CVS Price-Gouging Suit
• Feds' Oversight Found Lacking On Energy-Saving Deal
• Inside The Dispute Over $2B Deal For Future Roundup Claims
• Gilead Wants Harsher Sanctions For Kickbacks Whistleblower
• Colo. Laws Can't Make It Harder To Prove Medical Pot Defense
• Terms Of $2.8B Genomic Sale Shield Deal, Chancery Told
• Arent Fox Chases Pharmaceutical Co. For Unpaid Legal Fees
• Opening Args In NY Opioid Trial Set For End Of June
• $8M Asbestos Win Stands In Secondhand Exposure Death Suit
• Med Buyers Say Mallinckrodt Too Incompetent To Run Ch. 11
• DOJ, HHS Watchdog Warn Vaccines Must Be Free
• Missouri Pot Regulators Can't Keep Applications Secret
• Boston Marriott Hits Insurer For Limiting Virus Coverage
• BD Building $202M Manufacturing Facility In Spain
• Justices Must Weigh Class Cert. Denial Stats In Goldman Case
• Courts Are Aligning Patent Fraud, Inequitable Conduct Claims
• Aggregating Claimant And Case Data In Mass Torts
• Coronavirus Regulations: A State-By-State Week In Review
• Judging A Book: Rodriguez Reviews 'When Machines Can Be Judge'
• With Roe's Future In Doubt, Here's How The Justices May Rule
• FTC Takes Disgorgement Off Table In Surescripts Case
• Kodak Says NY Has Threatened To File Insider Trading Suit
• Utah Appellate Court Won't Redo Pot Licensing Decision
• Real Estate Rumors: Longfellow, Gomez, CVS
• Novartis Can't Claw Back Atty Email In Terbutaline Drug Suit
• Shkreli Cos.' Ability To Pay Penalties Irrelevant, FTC Says
• Alabama Legalizes Medical Pot With Restrictive Law
• Cooley Lands In Chicago With 10-Partner Team
• Imerys Seeks Permission To Pursue Ch. 11 Acquisitions
• High Court Won't Review Enbrel Patent Ruling
• FTC Continues Crackdown On CBD Sellers' Cure-All Claims
• 11th Circ. Won't Rethink Revival Of Lab Trustee's $31M Suit
• High Court Won't Hear $70M Risperdal Verdict Challenge
• Justices To Weigh Abortion Case That Could Upend Roe
• DEA Opens Up Pot Research With Scientist Agreements
• 9th Circ. Won't Wipe Out $25M Roundup Verdict
• Buyers Win Cert. In Ranbaxy Generic-Drug Antitrust Case
• USPTO Will Expedite Appeals, Oppositions For Virus TM Apps
• AGs Say High Court Ruling Doesn't Weaken Drug Price Claims
• Eye Care Chain MyEyeDr. Hit With TCPA Suit
• 9th Circ. Says EPA Must Revisit Lead-Related Standards
• HHS Defends Medicare Drug Program Cuts At High Court
• Ecolab Inks $2.5M OT Deal With Dozens Of Workers
• Let's End The Offshoring Of US Patents
• Minn. House OKs Legalizing, Taxing Recreational Marijuana
• Brand Battles: Crips LLC Faces TM Fight Over Name
• Fla. Appellate Court Tosses Investors From $17M Pot Co. Suit
• EU Medical Device Regulation May Spur Litigation Uptick
• How Early Data Analysis Can Inform FCA Litigation Strategy
• Health Hires: Sheppard Mullin, Galecto, LogicBio
• Miss. High Court Overturns Medical Pot Ballot Measure
• Cooley-Led Biotech Prices IPO Low As More Companies Delay
• Philips Slaps MRI Repair 'Hacker' With Trade Secret Suit
• Philly Judge OKs Investors' $4M CBD Study Settlement Deal
• 5 Steps For Law Firms Rethinking Flexible Work Post-COVID
• PBMs Aren't Ready To Throw In Towel In Preemption Fight
• Vaxart Investors Can Tweak Stock Claims Over COVID Vaccine
• Okla. Says Pot's Federal Illegality Dooms Residency Challenge
• Indivior Wants Ex-Worker's Retaliation Claims Thrown Out
• Groups Tell 11th Circ. To Flip Roundup Cancer Link Ruling
• IP Forecast: Cox Case To Restart Patent Jury Trials In Del.
• Kirkland, Ellenoff Guide Biotech SPAC's $200M IPO
• Life Sciences Real Estate Boom May Outlast Logistics Rush
• UCB Can't Halt Drug Ingredient Import In Vimpat IP Case
• COVID IP Waiver Doesn't Resolve Vaccine Production Barriers
• Moderna's Appeal Based On 'Imagined' Error, Fed. Circ. Told
• Life Sciences Software Biz Axtria Lands $150M In Funding
• Attys 'Wasting Time' In Sluggish Opioid Trial: Calif. Judge
• UNC Prof. Testifies That Stem Cell Clinic's Treatment Is Safe
• Medical Device Co. Sues Over Ex-Worker's Move To Medtronic
• Judge Halts Crab Harvest In SC Wildlife Refuge
• AdventHealth Wins $1.5M From PPE Fraud Settlement Default
• Challenging Class Cert. When Plaintiffs Missed 'False' Ad
• Tai Clashes With Senators Over COVID-19 Vaccine IP Waiver
• 2nd Circ. Won't Revive Suit Against Pfizer Over Lipitor
• Rosen Law Will Lead Walmart Investor Suit In Delaware
• 5 Firms Guide CD&R's £2.6B Bet On UDG
• Purdue's Ch. 11 Confirmation Hearing Set For August
• Judge's Rebuke Of Mass. AG Has Lessons For All Attorneys
• Walmart Wants 5th Circ. To Revive Opioid Suit Against Feds
• Hartford Wants Out From Ill. Toxic Emissions Suit Coverage
• FDA Investigator Says Stem Cell Clinic Lacked Documentation
• Elizabeth Holmes' Mystique Unlikely To Survive Looming Trial
• Senate Confirms Andrea Palm As HHS Deputy Secretary
• Tesaro Directors Slam 'Innuendo' In Del. Suit Over $5.1B Sale
• Fed. Circ. Backs Oxford Nanopore's DNA Tech IP Trial Victory
• Wife Cannot Sue Spouse's Co. Over Her COVID-19 Infection
• 3M's Expert Nixed From Earplug MDL Bellwether Case
• Dem Commissioner Blasts 'Pro-Merger' Pharma Stance At FTC
• AbbVie Slapped With Suit From Would-Be Humira Rival
• Texas Pharma Co. Settles Opioid Whistleblower Suit For $2.8M
• COVID IP Waiver Still Has Doubters In Europe, Industry
• Coronavirus Regulations: A State-By-State Week In Review
• USPTO Grants US Patent No. 11,000,000
• Insulin Pump Maker Says Roche Sneaked Into Market
• Font Considerations To Give Your Legal Briefs An Edge
• Ginkgo Bioworks Valued At $15B In SPAC Deal Led By 3 Firms
• 1st Circ. Agrees Ex-Tech Firm Execs 'Instrumental' In Scheme
• UMiami Pays $22M To Settle Medicare Overbilling FCA Suit
• GSK Gets Fines Slashed In UK Pay-For-Delay Case
• Natera Cancer Test Infringes Invitae Patent, Suit Alleges
• Aqua Pennsylvania Hits Slew Of Chem Cos. With PFAS Suit
• Westco Chemicals Reaches ERISA Class Action Settlement
• How Biden's First 100 Days Will Affect Gov't Contractors
• Justices Must Resolve Off-Label Drug Warning Predicament
• Cooley-Led Construction Software, Biotech Firms Prep IPOs
• Make Profitability Management Part Of Your Law Firm Culture
• Full Fed. Circ. Won't Review Becton's Wins On Drug Dosing IP
• FDA Dr. Says Stem Cell Clinics' Study 'Just A Bunch Of Words'
• Investors, CBD Pharma Co. Reach Deal Over Clinical Trial Suit
• With US On Board, COVID IP Waiver Still Faces Long Road
• Pharmacies Seek Appeal On Opioid Duties In Tribal Bellwether
• Cannabis Bill Roundup: Medical Pot Advances In The South
• Fed Circ. Revives Pharmacist's Whistleblower Case
• SC County Nixes Plan To Pay Fed. Judge Cut Of Opioid Money
• Endo Wants Stay Of $2.4B Opioid Baby Trial Pending Appeals
• Medical Pot Co. Says IT Biz Faked Signature In $10M Contract
• Merck Sued Over Asthma Drug's Alleged Psychiatric Effects
• Cell Therapy, Cannabinoid Biotechs Go Public For $171M
• Health Hires: Manatt, Fenwick, Foley Hoag
• Dermatology Case Tapped As Bellwether In Generic Drug MDL
• Fed. Circ. Backs Bracco Patent Losses At ITC, PTAB
• Purdue Asks For Another Month's Hold On Opioid Suits
• UK Litigation Roundup: Here's What You Missed In London
• Clinics' Stem Cell Treatments Endanger Patients, DOJ Says
• Ex-Theranos CEO Vies To Shield Jury From Wealth, Reportage
• 4th Circ. Mulls 'Murky' Law Around Small Zetia Buyer Class
• Generic Drug Cos. Invoke FTC Restitution Limits Against AGs
• 4 Firms Steer French COVID-19 Vaccine Maker's $94M US IPO
• Nephron To Receive $7.9M To End Trade Secrets Case
• Deals Rumor Mill: IHH Healthcare, Tricor, Reebok
• Blue Cross Unit Wants To Lead If Shkreli Faces New Suits
• 10x Launches Patent Suit Against NanoString
• 1st Circ. Hints Insys Execs' Convictions Will Stand
• Skin Care Co. Sued Over 'Mineral-Based' Sunscreen Labeling
• Drafting Clearer Patent Claims After Fed. Circ. L'Oreal Ruling
• Quest Pharmaceuticals Loses In Opioid Liability Coverage Suit
• Insurer Says It Needn't Cover Massage Oil Class Action
• 4 Trends In Discoverability Of Litigation Funding Documents
• Ex-Theranos CEO Blasts Government's Expert Witness Plan
• Opioid Crisis Is In Hospital's Front Yard, Doctor Testifies
• Generic-Drug Makers Knock States' Objection To Sanctions
• Pharma Co. Says €140M Award Suit Doesn't Belong In Mass.
• 11th Circ. Urged To Reverse Roundup Failure-To-Warn Ruling
• Judge Seeks Teva's Take On Morgan Lewis Conflict Claim
• Full 5th Circ. Redo Sought In Sanofi Chemo Hair Loss Suit
• Quest Can't Ditch ERISA Class Action Over 401(k) Investments
• Blackstone Exec Fearful Of A 'Torrent Of Economic Activity'
• Allergan Can't Escape NJ Defective Breast Implant Claims
• Chickasaw Nation Says CVS Misframes Drug Repayment Suit
• High Court's AMG Ruling Could Hinder FDA Enforcement
• Expect Increasing Scrutiny Of Wage-Fixing, No-Poach Deals
• Pfizer Loses Bid To Toss COVID-19 Vaccine IP Case
• W.Va. Consumer Law Changes Offer Help For Finance Cos.
• Biden Administration Backs IP Waiver On COVID-19 Vaccines
• Keep Junk Science Away From Juries
• Bio-Rad Ruling Highlights IP Assignment Clause Limits
• MiMedx Slams Quinn Emanuel Fees As 2 Other Firms Settle
• Buchanan Ingersoll Adds Former FDA Atty, Director
• Ex-Theranos CEO's Defense Emerges In Pre-Trial Battle
• 'Gateway Effect' Is Instant Flashpoint In Opioid MDL's 1st Trial
• 2 Firms Edge Out Peers As IPO Market Endures SPAC Slump
• Mass. AG Presses Pharmacies On Vaccine Patient Data Use
• Defunct Wholesaler Fights Renewed DQ Bid In Suboxone Case
• Real Estate Cos. More Optimistic Amid Vaccine Rollout
• Sanofi Wins $17.2M Fees, Expenses After Ditching FCA Suit
• Merck Unit Fined €7.5M For Hiding Project In EU M&A Review
• Cannabis Legalization's Effects On Insurance Industry
• 4th Circ. Says Va. County Opioid Claims Belong In Fed. Court
• Coronavirus Regulations: A State-By-State Week In Review
• 7 Lessons For Young Lawyers Starting Their Careers
• Teva Kicks Off Trial To Revoke Bayer's Cancer Drug Patent
• McKesson Wants Quick Win In Opioid Suit Coverage Battle
• Biden's HHS To Cover COVID Vaccine Administration Costs
• Opioid Reps Taught To Ease Doctors' Doubts, Witness Says
• Neal Gerber Nabs Green Griffith Patent Pro
• Sanofi Misled Buyers About Pain Relief Patches, Suit Says
• More Suits Allege Herbicide Paraquat Causes Parkinson's
• CBD Co. Zynerba, Investors Seek OK For $4M Settlement Deal
• Surgeon's Alleged Scheme Brings $33M In DOJ Settlements
• Global E-Commerce Firm Leads Quartet Of IPO Launches
• Bayer Wants To Shake Off Flea & Tick Drugs Antitrust Suit
• Bay Area Life Sciences Campus Snags $400M Loan
• Feds Want Harsher Prison Terms In Meningitis Outbreak Case
• At W.Va. Opioid Trial, Drug Cos. Battle 'Occam's Razor'
• Drug Developer Roivant Hits $7.3B Valuation In SPAC Merger